Jasmin Barman-Aksoezen

Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study

X. Schneider-Yin, E. Minder, A. Minder, 2021, Therapeutic advances in rare disease.

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders

X. Schneider-Yin, E. Minder, Jasmin Barman-Aksoezen, 2017, Clinical Pharmacokinetics.

Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity

D. Girelli, X. Schneider-Yin, E. Minder, 2017, Journal of Inherited Metabolic Disease.

Existing therapies and therapeutic targets for erythropoietic protoporphyria

X. Schneider-Yin, E. Minder, Jasmin Barman-Aksoezen, 2016 .

Iron in erythropoietic protoporphyrias: Dr. Jekyll or Mr. Hyde?

X. Schneider-Yin, E. Minder, Jasmin Barman-Aksoezen, 2017 .

The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding

G. Rogler, S. Vavricka, X. Schneider-Yin, 2018, United European gastroenterology journal.